Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cheaper psoriasis drug on the horizon? new biosimilar enters human trials

NCT ID NCT07258745

Recruiting now Disease control Sponsor: Chong Kun Dang Pharmaceutical Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 1 trial tests a new biosimilar called CKD-704, which is designed to be a more affordable copy of the psoriasis drug Skyrizi (risankizumab). The study involves 213 healthy adults who will receive a single dose of either CKD-704, the EU-approved Skyrizi, or the US-licensed Skyrizi. Researchers will compare how the body processes each drug and check for any safety issues.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CKD-704 (a biosimilar of risankizumab, the active ingredient in Skyrizi)
What this could lead to
If successful, this could provide a more affordable treatment option for psoriasis and other inflammatory conditions.
What could go wrong
This is an early Phase 1 trial in healthy volunteers, not patients. It only tests short-term safety and drug levels, not whether the biosimilar actually works for psoriasis. Biosimilars can sometimes differ in effectiveness or side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PSORIASIS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • MTZ powered by Pratia

    RECRUITING

    Warsaw, Warszawa, 02-172, Poland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.